Treatment with apolipoprotein A-1 mimetic peptide reduces lupus-like manifestations in a murine lupus model of accelerated atherosclerosis
Authors:
- Jennifer Mp WooJWJennifer Mp Woo
- Zhuofeng LinZLZhuofeng Lin
- Mohamad NavabMohamad Navab
- Casey Van DyckCDCasey Van Dyck
- Yvette Trejo-LopezYTYvette Trejo-Lopez
- Krystal Mt WooKWKrystal Mt Woo
- Hongyun LiHLHongyun Li
- Lawrence W CastellaniLCLawrence W Castellani
- Xuping WangXWXuping Wang
- Noriko IikuniNINoriko Iikuni
- Ornella J RulloOROrnella J Rullo
- Hui WuHWHui Wu
Open Access
- 18 May 2010
- journal article
- research article
- Published by Springer Nature in Arthritis Research & Therapy
- Vol. 12 (3) , R93
Abstract
Introduction: The purpose of this study was to evaluate the effects of L-4F, an apolipoprotein A-1 mimetic peptide, alone or with pravastatin, in apoE-/-Fas-/-C57BL/6 mice that spontaneously develop immunoglobulin G (IgG) autoantibodies, glomerulonephritis, osteopenia, and atherosclerotic lesions on a normal chow diet.Methods: Female mice, starting at eight to nine weeks of age, were treated for 27 weeks with 1) pravastatin, 2) L-4F, 3) L-4F plus pravastatin, or 4) vehicle control, followed by disease phenotype assessment.Results: In preliminary studies, dysfunctional, proinflammatory high-density lipoproteins (piHDL) were decreased six hours after a single L-4F, but not scrambled L-4F, injection in eight- to nine-week old mice. After 35 weeks, L-4F-treated mice, in the absence/presence of pravastatin, had significantly smaller lymph nodes and glomerular tufts (PL,LP< 0.05), lower serum levels of IgG antibodies to double stranded DNA (dsDNA) (PL< 0.05) and oxidized phospholipids (oxPLs) (PL,LP< 0.005), and elevated total and vertebral bone mineral density (PL,LP< 0.01) compared to vehicle controls. Although all treatment groups presented larger aortic root lesions compared to vehicle controls, enlarged atheromas in combination treatment mice had significantly less infiltrated CD68+macrophages (PLP< 0.01), significantly increased mean α-actin stained area (PLP< 0.05), and significantly lower levels of circulating markers for atherosclerosis progression, CCL19 (PL,LP< 0.0005) and VCAM-1 (PL< 0.0002).Conclusions: L-4F treatment, alone or with pravastatin, significantly reduced IgG anti-dsDNA and IgG anti-oxPLs, proteinuria, glomerulonephritis, and osteopenia in a murine lupus model of accelerated atherosclerosis. Despite enlarged aortic lesions, increased smooth muscle content, decreased macrophage infiltration, and decreased pro-atherogenic chemokines in L-4F plus pravastatin treated mice suggest protective mechanisms not only on lupus-like disease, but also on potential plaque remodeling in a murine model of systemic lupus erythematosus (SLE) and accelerated atherosclerosis.Keywords
This publication has 56 references indexed in Scilit:
- Oxidized lipids enhance RANKL production by T lymphocytes: Implications for lipid-induced bone lossClinical Immunology, 2009
- Interferon‐regulated chemokines as biomarkers of systemic lupus erythematosus disease activity: A validation studyArthritis & Rheumatism, 2009
- A novel method for oral delivery of apolipoprotein mimetic peptides synthesized from all L-amino acidsJournal of Lipid Research, 2009
- Dysfunctional proinflammatory high‐density lipoproteins confer increased risk of atherosclerosis in women with systemic lupus erythematosusArthritis & Rheumatism, 2009
- Accelerated atherosclerosis in ApoE deficient lupus mouse modelsClinical Immunology, 2008
- Atorvastatin has hypolipidemic and anti-inflammatory effects in apoE/LDL receptor-double-knockout miceLife Sciences, 2008
- Measurement of Collagen and Smooth Muscle Cell Content in Atherosclerotic Plaques Using Polarization-Sensitive Optical Coherence TomographyJACC, 2007
- Enhanced Expression of the Homeostatic Chemokines CCL19 and CCL21 in Clinical and Experimental AtherosclerosisArteriosclerosis, Thrombosis, and Vascular Biology, 2007
- Granulocyte Macrophage Colony-Stimulating Factor Regulates Dendritic Cell Content of Atherosclerotic LesionsArteriosclerosis, Thrombosis, and Vascular Biology, 2007
- Immune dysregulation accelerates atherosclerosis and modulates plaque composition in systemic lupus erythematosusProceedings of the National Academy of Sciences, 2006